AUTHORS
Yaonan Hong, Shiyue Wu2, Shun He3, Jingjie Dong4, Qi Liu5, Xiawan Yang6, Yingying Shen7, Tonglin Hu8, Keding Shao9, Yuhong Zhou10, Zehua Liang11, Dijiong Wu, MD,PhD12
AFFILIATIONS
1 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
2 Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
3 Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
4 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
5 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
6 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
7 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
8 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
9 Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
10 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
11 Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
12 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
ABSTRACT
Aplastic anemia (AA) is a life-threatening bone marrow failure disorder in which hematopoietic stem cell (HSC) attrition is a central pathological hallmark. HSCs rely on tightly regulated protein synthesis and low reactive oxygen species (ROS) to maintain quiescence and long-term self-renewal capacity. However, many AA patients become transfusion-dependent over time, leading to secondary iron overload. Excess labile iron catalyzes ROS generation via the Fenton reaction, driving lipid peroxidation and predisposing HSCs to ferroptosis. Human HSCs are intrinsically vulnerable to ferroptosis due to their unique reliance on low-protein-synthesis homeostasis. Although ferroptosis-related genes have been identified in the bone marrow of AA patients, the specific molecular drivers linking iron overload to ferroptosis-mediated HSC attrition remain poorly defined, and pharmacological agents that directly interrupt this axis to preserve HSC function are still lacking. BuShen Huoxue Formula (BHF), a traditional Chinese medicine (TCM) refined from the “kidney-tonifying and blood-activating” principle, has demonstrated clinical benefits in AA with iron overload. We previously showed that BHF alleviates ferroptosis in bone marrow stromal cells and that its components possess iron-chelating properties, but its molecular mechanism and therapeutic target remain undefined. Here, we integrated single-cell RNA seq, UPLC-MS/MS, bulk RNA-seq, IP-MS, and functional assays to systematically delineate the therapeutic mechanism of BHF in AA and to pinpoint its potential bioactive compounds.
In an iron-overloaded AA mouse model, BHF significantly improved peripheral blood counts, reduced bone marrow apoptosis and iron deposition, and attenuated systemic oxidative stress (decreased MDA, increased GSH and SOD; P < 0.05). Single-cell RNA sequencing of AA patient bone marrow samples (GSE181989) revealed profound HSPC loss (1.42% vs. 53.60% in healthy donors) accompanied by ferroptosis and p53 pathway enrichment; virtual gene knockout analysis identified HDAC8 as a critical regulator of this process. In vitro, BHF-containing serum dose-dependently reversed erastin-induced ferroptotic phenotypes in 32D cells. BHF significantly reduced the proportion of PI-positive cells from 38.09% to 13.51% (P < 0.001), restored cell cycle progression by decreasing G0/G1 arrest and increasing S-phase entry (P < 0.01), and attenuated mitochondrial damage in a dose-dependent manner (P < 0.05). BHF also suppressed lipid peroxidation, reduced intracellular ROS and LPO levels (P < 0.05), and corrected aberrant autophagosome accumulation and lysosomal dysfunction induced by erastin. Mechanistically, BHF upregulated HDAC8 expression, suppressed p53 acetylation, and restored the expression of SLC7A11 and GPX4 (P < 0.05). CETSA confirmed the direct interaction of specific BHF-derived compounds with HDAC8, enhancing its thermal stability. IP-MS identified 55 HDAC8-interacting proteins including p53, and RIP confirmed enrichment of p53 mRNA in HDAC8 pull-downs (P < 0.001), indicating dual regulation at post-translational and post-transcriptional levels. Critically, the therapeutic benefits of BHF, including the normalization of peripheral blood profiles, recovery of HSC self-renewal capacity, and inhibition of ferroptotic cell death, were significantly abrogated in conditional HDAC8-deficient mice (Mx1-Cre HDAC8f/f). Bulk RNA sequencing of LSK cells demonstrated that BHF restored mitochondrial homeostasis and oxidative phosphorylation, essential for protecting HSPCs against ferroptosis. Furthermore, UPLC-MS/MS coupled with network pharmacology identified 85 circulating prototype compounds and metabolites in BHF, predominantly flavonoids, terpenes, and phenolics, network pharmacology and molecular dynamics simulations supported direct binding of several compounds (including α-glycyrrhizin and anthraquinone derivatives) to HDAC8
In summary, this study establishes ferroptosis as a therapeutically actionable mechanism underlying HSPC attrition in AA, particularly in the context of iron overload, and identifies HDAC8 as a critical regulatory node. BHF directly targets HDAC8 to inhibit p53-mediated ferroptosis and preserve HSPC function. These findings provide promising therapeutic strategies for AA and deepen the understanding of the mechanisms underlying traditional Chinese medicine.
DISCLOSURES
Yaonan Hong: No relevant conflicts of interest to declare.